Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
Osteoporosis, Vascular Calcification, Inflammation
About this trial
This is an interventional treatment trial for Osteoporosis focused on measuring nutritional supplement, dietary supplement, vitamin therapy, Vitamin K deficiency, bone density
Eligibility Criteria
Inclusion Criteria: Ambulatory general population Dietary intake of vitamin K below 120 mcg Exclusion Criteria: Unable to give informed consent Usual dietary intake of phylloquinone greater than 120 µg/d Usual dietary calcium intake greater than 1500 mg/d Usual dietary vitamin D intake greater than 1500 IU Women less than 5 years postmenopausal Femoral neck BMD (bone mineral density) at screening that is greater than 1.8 SD above or below an age-matched reference mean 24-hour calcium to creatinine ratio exceeding 300 mg/g for women or 350 mg/g for men Terminal illness Renal or liver disease requiring treatment Kidney stone in the past 5 years Current hyperparathyroidism Bilateral hip surgery Treatment with a bisphosphonate, calcitonin, estrogen progestin, androgen, tamoxifen, or fluoride (other than dental rinse), or any other treatment for osteoporosis in previous 3 months Warfarin or anticoagulant use in the past 12 months Nonambulation Known coronary disease, defined by myocardial infarction or unstable angina Prior open heart surgery Atrial fibrillation
Sites / Locations
- Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University